<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01930214</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-0002-P</org_study_id>
    <nct_id>NCT01930214</nct_id>
  </id_info>
  <brief_title>Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)</brief_title>
  <acronym>MACE</acronym>
  <official_title>Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovascular Systems Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiovascular Systems Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the current standard of care treatment outcome in
      none/mild, moderate and severely calcified coronary lesions using:

        -  A composite of MACE at 30-day and one (1) year post procedure, and

        -  Procedural and lesion success
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, non-randomized, multi-center study includes subjects who meet all of the
      inclusion and none of the exclusion criteria and sign the ICF. This study may treat up to
      approximately 500 subjects at up to 50 active sites in the U.S. Subjects may be followed up
      to three (3) years. Subjects will be stratified into one (1) of three (3) arms based on the
      degree of calcification in the coronary lesion as defined by this protocol. The duration of
      the study is expected to be approximately four (4) years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2013</start_date>
  <completion_date type="Actual">June 1, 2017</completion_date>
  <primary_completion_date type="Actual">November 7, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MACE at 30 Days</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>A Kaplan-Meier analysis was performed to determine the percent probability that a study participant experienced a major adverse cardiac event through 30 days.
30-day MACE is composed of:
Cardiac death
Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave
Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE at One (1) Year</measure>
    <time_frame>One (1) year post procedure</time_frame>
    <description>A Kaplan-Meier analysis was performed to determine the percent probability that a study participant experienced a major adverse cardiac event through 1 year.
1-year MACE is composed of:
Cardiac death
Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave
Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>Participants were followed from baseline procedure through hospital discharge, an expected average of 24 hours</time_frame>
    <description>Procedural success is defined as success in facilitating stent delivery with a residual stenosis of &lt;50% and without the occurrence of an in-hospital MACE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Success</measure>
    <time_frame>During the procedure</time_frame>
    <description>Lesion success is defined as success in facilitating stent delivery with a post-procedural result of &lt;50% residual stenosis for a given lesion treated during the procedure without severe angiographic complications.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">350</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>None/mild calcification</arm_group_label>
    <description>Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Calcification</arm_group_label>
    <description>Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe calcification</arm_group_label>
    <description>Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Coronary Intervention</intervention_name>
    <description>Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
    <arm_group_label>Moderate Calcification</arm_group_label>
    <arm_group_label>None/mild calcification</arm_group_label>
    <arm_group_label>Severe calcification</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        18 years or older who are scheduled for percutaneous coronary revascularization involving
        stent.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be at least 18 years of age.

          2. Subjects must be scheduled for percutaneous coronary revascularization involving stent
             deployment in de novo coronary lesions. Percutaneous coronary revascularization is
             defined as treatment with commercially available devices that may include but not
             limited to balloon angioplasty, cutting balloon, rotablation, etc. followed by the
             stent placement.

          3. Subjects CK-MB must be less than or equal to the upper limit of lab normal value
             within eight (8) hours prior to procedure. If CK-MB results are not yet available
             prior to initiating procedure, subjects Troponin I or Troponin T must be less than or
             equal to the upper limit of lab normal value within eight (8) hours prior to the
             procedure.

          4. The target lesion must be a de novo coronary lesion that has not been previously
             treated with any interventional procedure.

          5. The target vessel must be a native coronary artery with:

               1. A stenosis ≥ 70% and &lt; 100%, or

               2. A stenosis ≥ 50% &lt; 70% with evidence of clinical ischemia

          6. The target vessel reference diameter must be ≥ 2.5mm and ≤ 4.0 mm.

          7. The lesion length must not exceed 40 mm.

          8. The target vessel must have a Thrombolysis In Myocardial Infarction (TIMI) flow three
             (3) at baseline.

        Exclusion Criteria:

          1. Inability to understand the study or a history of non-compliance with medical advice.

          2. Unwilling or unable to sign the MACE clinical study ICF.

          3. History of any cognitive or mental health status that would interfere with study
             participation.

          4. Currently enrolled in any other pre-approval investigational study. This does not
             apply to long-term post-market studies unless these studies might clinically interfere
             with the current study endpoints (e.g., limit use of study-required medication, etc.).

          5. Female subjects who are pregnant or planning to become pregnant within the study
             period.

          6. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or
             clopidogrel without adequate alternative medications.

          7. Known sensitivity to contrast media, which cannot be adequately pre-medicated.

          8. Diagnosed with chronic renal failure unless under hemodialysis, or has a serum
             creatinine level &gt;2.5 mg/dl.

          9. History of major cardiac intervention within 30-day, not including a PCI procedure for
             a staging purpose.

         10. Evidence of heart failure by one of the following:

             i. Left Ventricular Ejection Fraction (LVEF) ≤ 25% ii. New York Heart Association
             (NYHA) class III or IV iii. Clinical symptoms

         11. History of a stroke or transient ischemic attack (TIA) within six (6) months

         12. Active peptic ulcer or upper gastrointestinal (GI) bleeding within six (6) months.

         13. History of bleeding diathesis or coagulopathy or intention to refuse blood transfusion
             if one should become necessary.

         14. Concurrent medical condition with a life expectancy of &lt; 36 months.

         15. History of immune deficiency.

         16. Uncontrolled insulin dependent diabetes.

         17. Evidence of active infections on the day of the index procedure.

         18. Subject has planned cardiovascular intervention within 60 days post index procedure.

         19. Subject with angiographically confirmed evidence of more than two (2) lesions within
             one (1) vessel or more than one (1) vessel requiring intervention, unless the
             treatment is staged. See Section 10.1 for more details.

         20. Target lesion is located in a native vessel distal to anastomosis with a saphenous
             vein graft or Left Internal Mammary Artery/ Right Internal Mammary Artery (LIMA/RIMA)
             bypass.

         21. Target vessel has angiographically visible or suspected thrombus.

         22. Target vessel appears to be/is excessively tortuous at baseline.

         23. Target lesion is an ostial location (within 5mm of ostium) or an unprotected left main
             lesion.

         24. Target lesion is a bifurcation (side branch ≥ 1.5mm).

         25. Treatment of the target lesion with the CSI coronary Diamondback Orbital Atherectomy
             System (OAS).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samin K Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clearwater Cardiovascular &amp; Interventional Consultants</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center Heart Institute</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of NW Florida</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents Research Institute</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Education &amp; Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>00119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Bay Regional</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boone Hospital</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jersey Shore Medical Center</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Heart &amp; Vascular Specialists</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Health System</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Pittsburg MC - Hamot</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Research Institute</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health Center</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sharma SK, Bolduan RW, Patel MR, Martinsen BJ, Azemi T, Giugliano G, Resar JR, Mehran R, Cohen DJ, Popma JJ, Waksman R. Impact of calcification on percutaneous coronary intervention: MACE-Trial 1-year results. Catheter Cardiovasc Interv. 2019 Aug 1;94(2):187-194. doi: 10.1002/ccd.28099. Epub 2019 Jan 25.</citation>
    <PMID>30681262</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 21, 2013</study_first_submitted>
  <study_first_submitted_qc>August 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <results_first_submitted>December 17, 2018</results_first_submitted>
  <results_first_submitted_qc>April 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2019</results_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was completed at 350 treated subjects.</recruitment_details>
      <pre_assignment_details>A subject was considered enrolled when a signed informed consent was in place, all inclusion/no exclusion criteria were met, and the study guidewire had crossed the target lesion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>None/Mild Calcification</title>
          <description>Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
        </group>
        <group group_id="P2">
          <title>Moderate Calcification</title>
          <description>Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
        </group>
        <group group_id="P3">
          <title>Severe Calcification</title>
          <description>Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary withdrawal of infomed consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline population summarizes data from 350 enrolled subjects. Outcome Measures data includes the 346 subjects with sufficient angiography for core lab stratification.</population>
      <group_list>
        <group group_id="B1">
          <title>None/Mild Calcification</title>
          <description>Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
        </group>
        <group group_id="B2">
          <title>Moderate Calcification</title>
          <description>Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
        </group>
        <group group_id="B3">
          <title>Severe Calcification</title>
          <description>Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="117"/>
            <count group_id="B3" value="133"/>
            <count group_id="B4" value="350"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.9" spread="10.3"/>
                    <measurement group_id="B2" value="68.9" spread="10.6"/>
                    <measurement group_id="B3" value="69.3" spread="9.2"/>
                    <measurement group_id="B4" value="67.3" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="331"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MACE at 30 Days</title>
        <description>A Kaplan-Meier analysis was performed to determine the percent probability that a study participant experienced a major adverse cardiac event through 30 days.
30-day MACE is composed of:
Cardiac death
Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave
Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure</description>
        <time_frame>30 days post procedure</time_frame>
        <population>Subjects were enrolled based on Investigator assessment of calcium; however, all analyses were performed by core lab assessed calcium to ensure consistent methodology. Of the 350 subjects enrolled in the study, 346 had sufficient angiography for core lab stratification (133 none/mild, 99 moderate, and 114 severe).</population>
        <group_list>
          <group group_id="O1">
            <title>None/Mild Calcification</title>
            <description>Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis as assessed by the angiographic core lab.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
          </group>
          <group group_id="O2">
            <title>Moderate Calcification</title>
            <description>Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion as assessed by the angiographic core lab.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
          </group>
          <group group_id="O3">
            <title>Severe Calcification</title>
            <description>Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion as assessed by the angiographic core lab.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
          </group>
        </group_list>
        <measure>
          <title>MACE at 30 Days</title>
          <description>A Kaplan-Meier analysis was performed to determine the percent probability that a study participant experienced a major adverse cardiac event through 30 days.
30-day MACE is composed of:
Cardiac death
Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave
Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure</description>
          <population>Subjects were enrolled based on Investigator assessment of calcium; however, all analyses were performed by core lab assessed calcium to ensure consistent methodology. Of the 350 subjects enrolled in the study, 346 had sufficient angiography for core lab stratification (133 none/mild, 99 moderate, and 114 severe).</population>
          <units>Percent probability of MACE</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.0" upper_limit="6.5"/>
                    <measurement group_id="O3" value="15" lower_limit="8.4" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MACE at One (1) Year</title>
        <description>A Kaplan-Meier analysis was performed to determine the percent probability that a study participant experienced a major adverse cardiac event through 1 year.
1-year MACE is composed of:
Cardiac death
Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave
Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure</description>
        <time_frame>One (1) year post procedure</time_frame>
        <population>Subjects were enrolled based on Investigator assessment of calcium; however, all analyses were performed by core lab assessed calcium to ensure consistent methodology. Of the 350 subjects enrolled in the study, 346 had sufficient angiography for core lab stratification (133 none/mild, 99 moderate, and 114 severe).</population>
        <group_list>
          <group group_id="O1">
            <title>None/Mild Calcification</title>
            <description>Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis as assessed by the angiographic core lab.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
          </group>
          <group group_id="O2">
            <title>Moderate Calcification</title>
            <description>Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion as assessed by the angiographic core lab.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
          </group>
          <group group_id="O3">
            <title>Severe Calcification</title>
            <description>Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion as assessed by the angiographic core lab.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
          </group>
        </group_list>
        <measure>
          <title>MACE at One (1) Year</title>
          <description>A Kaplan-Meier analysis was performed to determine the percent probability that a study participant experienced a major adverse cardiac event through 1 year.
1-year MACE is composed of:
Cardiac death
Myocardial Infarction (MI) - defined as a Creatine Kinase Myocardial-Band Isoenzyme (CK-MB) level greater than three (3) times the Upper Limit of Lab Normal (ULN) value with or without new pathologic Q wave
Target Vessel Revascularization (TVR) - defined as a revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure</description>
          <population>Subjects were enrolled based on Investigator assessment of calcium; however, all analyses were performed by core lab assessed calcium to ensure consistent methodology. Of the 350 subjects enrolled in the study, 346 had sufficient angiography for core lab stratification (133 none/mild, 99 moderate, and 114 severe).</population>
          <units>Percent probability of MACE</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="1.5" upper_limit="9.2"/>
                    <measurement group_id="O2" value="8.5" lower_limit="2.8" upper_limit="14.2"/>
                    <measurement group_id="O3" value="24.2" lower_limit="16.1" upper_limit="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Procedural success is defined as success in facilitating stent delivery with a residual stenosis of &lt;50% and without the occurrence of an in-hospital MACE.</description>
        <time_frame>Participants were followed from baseline procedure through hospital discharge, an expected average of 24 hours</time_frame>
        <population>Subjects were enrolled based on Investigator assessment of calcium; however, all analyses were performed by core lab assessed calcium to ensure consistent methodology. Of the 350 subjects enrolled in the study, 346 had sufficient angiography for core lab stratification (133 none/mild, 99 moderate, and 114 severe).</population>
        <group_list>
          <group group_id="O1">
            <title>None/Mild Calcification</title>
            <description>Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis as assessed by the angiographic core lab.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
          </group>
          <group group_id="O2">
            <title>Moderate Calcification</title>
            <description>Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion as assessed by the angiographic core lab.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
          </group>
          <group group_id="O3">
            <title>Severe Calcification</title>
            <description>Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion as assessed by the angiographic core lab.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Procedural success is defined as success in facilitating stent delivery with a residual stenosis of &lt;50% and without the occurrence of an in-hospital MACE.</description>
          <population>Subjects were enrolled based on Investigator assessment of calcium; however, all analyses were performed by core lab assessed calcium to ensure consistent methodology. Of the 350 subjects enrolled in the study, 346 had sufficient angiography for core lab stratification (133 none/mild, 99 moderate, and 114 severe).</population>
          <units>Percent of Procedures</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="93.5" upper_limit="99.5"/>
                    <measurement group_id="O2" value="96" lower_limit="90.0" upper_limit="98.9"/>
                    <measurement group_id="O3" value="86.8" lower_limit="79.2" upper_limit="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Success</title>
        <description>Lesion success is defined as success in facilitating stent delivery with a post-procedural result of &lt;50% residual stenosis for a given lesion treated during the procedure without severe angiographic complications.</description>
        <time_frame>During the procedure</time_frame>
        <population>Subjects were enrolled based on Investigator assessment of calcium; however, all analyses were performed by core lab assessed calcium to ensure consistent methodology. Of the 350 subjects enrolled in the study, 346 had sufficient angiography for core lab stratification (133 none/mild, 99 moderate, and 114 severe).</population>
        <group_list>
          <group group_id="O1">
            <title>None/Mild Calcification</title>
            <description>Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis as assessed by the angiographic core lab.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
          </group>
          <group group_id="O2">
            <title>Moderate Calcification</title>
            <description>Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion as assessed by the angiographic core lab.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
          </group>
          <group group_id="O3">
            <title>Severe Calcification</title>
            <description>Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion as assessed by the angiographic core lab.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Success</title>
          <description>Lesion success is defined as success in facilitating stent delivery with a post-procedural result of &lt;50% residual stenosis for a given lesion treated during the procedure without severe angiographic complications.</description>
          <population>Subjects were enrolled based on Investigator assessment of calcium; however, all analyses were performed by core lab assessed calcium to ensure consistent methodology. Of the 350 subjects enrolled in the study, 346 had sufficient angiography for core lab stratification (133 none/mild, 99 moderate, and 114 severe).</population>
          <units>Percentage of Procedures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <desc>AE collection was limited to cardiac event, death, serious injury, MAEs, bleeding and angio complications related to the index procedure. Angio core lab (CL) assessed the presence of dissections and perforations; CEC adjudicated: bleed, angio events not assessed by CL, death, MI, TVR, TLR and any non-endpoint event that the CEC deemed necessary to adjudicate as study related. Groups based on CL calcification for 346/350; remaining (4) subjects were included based on site reported calcification.</desc>
      <group_list>
        <group group_id="E1">
          <title>None/Mild Calcification</title>
          <description>• Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
        </group>
        <group group_id="E2">
          <title>Moderate Calcification</title>
          <description>• Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
        </group>
        <group group_id="E3">
          <title>Severe Calcification</title>
          <description>• Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion.
Percutaneous Coronary Intervention: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute MI, Q-wave</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Acute MI, non Q-wave</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Acute congestive heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="23" subjects_affected="17" subjects_at_risk="134"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E3" events="21" subjects_affected="12" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Arrhythmia, unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Atrioventricular block, III degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chest Pain, non ischemic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chronic CHF, or exacerbation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Elevated CK-MB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Elevated Troponin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Elevated cardiac enzymes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Other cardiovascular system related AE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction to contrast dye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Infection, systemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Other index procedure related AE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Other infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Other patient condition related AE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abrupt or threatened closure of coronary artery</sub_title>
                <description>Angiographic complications</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Coronary artery vasospasm</sub_title>
                <description>Angiographic complications</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Coronary vessel dissection present (A-F)</sub_title>
                <description>Angiographic complications</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="134"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="99"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Coronary vessel perforation present</sub_title>
                <description>Angiographic complications</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Slow flow or no reflow phenomena</sub_title>
                <description>Angiographic complications</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident (CVA)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea/Shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis (DVT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hematoma at access site, not requiring intervention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hemorrhage, major, requiring transfusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hemorrhage, minor, without transfusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral artery pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral artery/vascular disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral vessel damage requiring surgical repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any previously unpublished information provided to the Investigators by the Sponsor is confidential and will remain the sole property of the Sponsor. The Investigator agrees to use this information only in accomplishing this study not use it for other purposes without the Sponsor’s written consent. An Investigator can generate additional publication ideas based on the trial data. The Sponsor reserves the right to review the manuscript prior to submission in order to verify accuracy of the data</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Project Manager</name_or_title>
      <organization>Cardiovascular Systems Inc.</organization>
      <phone>6512591600</phone>
      <email>clinicaltrials_csi@csi360.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

